Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2520-2523

  Ferrándiz, María José ^a   Oteo, Jesús ^b   Aracil, Belén ^b   Gómez Garcés, Jose Luis ^b   De La Campa, Adela G ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; BACTERIAL PROTEIN; CIPROFLOXACIN; CLINAFLOXACIN; ETHIDIUM BROMIDE; NORFLOXACIN; PHENYLALANINE; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SERINE; SPARFLOXACIN; TYROSINE; UNCLASSIFIED DRUG;

ALPHA HEMOLYTIC STREPTOCOCCUS; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG TRANSPORT; GENE MUTATION; GENE SEQUENCE; GENETIC RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

EID: 0345363286     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2520     Document Type: Article

References (31)

1. Ahmed, M., C. M. Borsch, A. A. Neyfakh, and S. Schuldiner. 1993. Mutants of the Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. J. Biol. Chem. 268:11086-11089.
2. Alcalde, F., J. Carratala, J. Liñares, F. Gudiol, and R. Martín. 1996. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob. Agents Chemotner. 40:2117-2120.
3. Alcalde, F., J. Liñares, R. Pallarés, J. Carratala, M. A. Benítez, F. Gudiol, and R. Martín. 1995. In vitro activity of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob. Agents Chemother. 39:2243-2247.
4. Awada, A. P., P. Van der Auwera, P. Meunier, D. Daneau, and J. Klastersky. 1992. Streptococcal and enterococcal bacteremia in patients with cancer. Clin. Infect. Dis. 15:33-48.
5. Baranova, N. N., and A. Neyfakh. 1997. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1396-1398.
6. Bochud, P. Y., P. H. Egglman, T. H. Calandra, G. Van Melle, L. Saghafi, and P. Francioli. 1994. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin. Infect. Dis. 18:25-31.
7. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
8. Carratala, J., F. Alcaide, A. Fernandez-Sevilla, X. Corbell, J. Liñares, and F. Gudiol. 1995. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin. Infect. Dis. 20:1169-1173.
9. Douglas, C. W. I., J. Heath, K. K. Hampton, and F. E. Preston. 1993. Identity of viridans streptococci isolated from cases of infective endocarditis. J. Med. Microbiol. 39:179-182.
10. Elting, L. S., G. P. Bodey, and B. H. Keefe. 1992. Septicemia and shock syndrome due to viridans streptococci: a case-control predisposing factors. Clin. Infect. Dis. 14:1201-1207.
11. Facklam, R. R., and J. A. Washington II. 1991. Streptococcus and related catalase-negative gram-positive cocci, p. 238-257. In W. J. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
12. Garnier, F., G. Gerbaud, P. Courvalin, and M. Galimand. 1997. Identification of clinically relevant viridans group streptococci to the species level by PCR. Antimicrob. Agents Chemother. 35:2337-2341.
13. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
14. Gonzalez, I., M. Georgiou, F. Alcaide, D. Balas, J. Liñares, and A. G. de la Campa. 1998. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob. Agents Chemother. 42:2792-2798.
15. Grinius, L. L., and E. B. Goldberg. 1994. Bacterial multidrug resistance is due to a single membrane protein which functions as a drug pump. J. Biol. Chem. 269:29998-30004.
16. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
17. Kikuchi, K., T. Enari, K. Totsuka, and K. Shimizu. 1995. Comparison of phenotypic characteristics, DNA-DNA hybridization results, and results with a commercial rapid biochemical and enzymatic reaction system for identification of viridans group streptococci. J. Clin. Microbiol. 33:1215-1222.
18. Markham, P. N., and A. A. Neyfakh. 1996. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:2673-2674.
19. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
20. Neyfakh, A. A. 1992. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein. Antimicrob. Agents Chemother. 36:484-485.
21. Neyfakh, A. A., V. Bidnenko, and L. B. Chen. 1991. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. USA 88:4781-4785.
22. Neyfakh, A. A., C. M. Borsch, and K. G. W. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129.
23. Ng, E. Y. W., M. Trucksis, and D. C. Hooper. 1994. Quinolone resistance mediated by norA: physiological characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38:1345-1355.
24. Poulsen, K., and M. Kilian. 1998. Program and abstracts of the American Society for Microbiology Conference on Streptococcal Genetics, abstr. 2D-05. American Society for Microbiology, Washington, D.C.
25. Roberts, R. B., A. G. Krieger, N. L. Schiller, and K. C. Gross. 1979. Viridans Streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci. Rev. Infect. Dis. 1:955-965.
26. Ruoff, K. L. 1995. Streptococcus, p. 299-307. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
27. Sussman, J. I., J. Baron, M. J. Tenenbaum, M. H. Kaplan, R. R. Greenspan, R. R. Facklam, M. B. Tyburski, M. A. Goldman, B. F. Kanzer, and R. A. Pizzarello. 1986. Viridans streptococcal endocarditis: clinical, microbiological, and echocardiographic correlations. J. Infect. Dis. 154:597-603.
28. Vandamme, P., U. Torck, E. Falsen, B. Pot, H. Goossens, and K. Hersters. 1998. Whole-cell protein electrophoretic analysis of viridans streptococci: evidence for heterogeneity among Streptococcus mitis biovars. Int. J. Syst. Bacteriol. 48:117-125.
29. Venditti, M., P. Baiocchi, C. Barandimarte, P. Serra, G. Gentile, C. Girmenia, and P. Martino. 1989. Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients. Antimicrob. Agents Chemother. 33:580-582.
30. Yoshida, H., M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172:6942-6949.
31. Zeller, V., C. Janoir, M.-D. Kitzis, L. Gutmann, and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.